PT2952209T - Formulações homogéneas compreendendo ácidos gordos poliinsaturados ómega-3 (n-3 pufa) e resveratrol para administração oral - Google Patents

Formulações homogéneas compreendendo ácidos gordos poliinsaturados ómega-3 (n-3 pufa) e resveratrol para administração oral

Info

Publication number
PT2952209T
PT2952209T PT140019415T PT14001941T PT2952209T PT 2952209 T PT2952209 T PT 2952209T PT 140019415 T PT140019415 T PT 140019415T PT 14001941 T PT14001941 T PT 14001941T PT 2952209 T PT2952209 T PT 2952209T
Authority
PT
Portugal
Prior art keywords
polynosaturated
pufa
resveratrol
fatty acids
oral administration
Prior art date
Application number
PT140019415T
Other languages
English (en)
Portuguese (pt)
Inventor
Santaniello Mosè
Giannini Giuseppe
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of PT2952209T publication Critical patent/PT2952209T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
PT140019415T 2014-06-04 2014-06-04 Formulações homogéneas compreendendo ácidos gordos poliinsaturados ómega-3 (n-3 pufa) e resveratrol para administração oral PT2952209T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14001941.5A EP2952209B1 (en) 2014-06-04 2014-06-04 Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration

Publications (1)

Publication Number Publication Date
PT2952209T true PT2952209T (pt) 2018-05-09

Family

ID=50884651

Family Applications (1)

Application Number Title Priority Date Filing Date
PT140019415T PT2952209T (pt) 2014-06-04 2014-06-04 Formulações homogéneas compreendendo ácidos gordos poliinsaturados ómega-3 (n-3 pufa) e resveratrol para administração oral

Country Status (13)

Country Link
US (1) US10300035B2 (enExample)
EP (1) EP2952209B1 (enExample)
JP (1) JP6552526B2 (enExample)
CN (1) CN106456783B (enExample)
AU (1) AU2015271277A1 (enExample)
CA (1) CA2943000A1 (enExample)
EA (1) EA032717B1 (enExample)
ES (1) ES2666836T3 (enExample)
MX (1) MX361765B (enExample)
PL (1) PL2952209T3 (enExample)
PT (1) PT2952209T (enExample)
UA (1) UA118289C2 (enExample)
WO (1) WO2015185238A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115607677B (zh) * 2022-05-06 2025-08-05 太阳雨林(北京)生物医药有限公司 预防、阻止或治疗微生物感染的复合物及其制备和应用
EP4520348A1 (en) * 2022-05-06 2025-03-12 Sunforest (Beijing) Biopharma Ltd Carbon chain substance for regulating transmembrane transport and fluidity of cell membranes, and preparation and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
DE602005026582D1 (de) * 2005-03-11 2011-04-07 Recon Oil Ind Private Ltd Synergistisch hitzestabiles ölmedium mit eicosapentaensäure (epa) und docosahexaensäure (dha)
DE202008003509U1 (de) * 2008-03-12 2009-10-15 Langhoff, Gertrud Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung der Arteriosklerose, sowie zur Schmerzbekämpfung und zur Entzündungshemmung
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
EA201200935A1 (ru) 2009-12-23 2012-12-28 Дефианте Фармасеутика С.А. Комбинированная композиция, подходящая для лечения сердечно-сосудистых заболеваний
WO2011120530A1 (en) 2010-03-31 2011-10-06 Lifecycle Phama A/S Porous tablets as carriers for liquid formulations
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
WO2011162802A1 (en) * 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
CN102228089B (zh) * 2011-06-22 2013-02-20 刘升胜 一种天然复合食用植物健脑营养饮料
KR101418980B1 (ko) * 2012-04-24 2014-07-11 (주)바이오제닉스 난용성 물질을 가용화 하는 다중 라멜라 액정의 제조방법
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014095628A1 (en) * 2012-12-17 2014-06-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)

Also Published As

Publication number Publication date
US20170119720A1 (en) 2017-05-04
JP2017516820A (ja) 2017-06-22
US10300035B2 (en) 2019-05-28
MX2016013190A (es) 2017-01-09
EA201692398A1 (ru) 2017-04-28
EP2952209A1 (en) 2015-12-09
EP2952209B1 (en) 2018-03-28
AU2015271277A1 (en) 2016-11-10
EA032717B1 (ru) 2019-07-31
CN106456783A (zh) 2017-02-22
JP6552526B2 (ja) 2019-07-31
ES2666836T3 (es) 2018-05-08
CA2943000A1 (en) 2015-12-10
MX361765B (es) 2018-12-17
WO2015185238A1 (en) 2015-12-10
CN106456783B (zh) 2020-06-12
UA118289C2 (uk) 2018-12-26
PL2952209T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
IL283545B1 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
PT3368507T (pt) Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
MA50541A (fr) Formulations pharmaceutiques
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
MA42303A (fr) Formulations pharmaceutiques
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
ZA201606929B (en) Compounds and compositions for inducing chondrogenesis
SG11201608217PA (en) Fatty acid composition and use thereof
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
BR112018011318A2 (pt) composições e métodos para higiene bucal
CL2020001456A1 (es) Formulaciones para apoyo nutricional en sujetos en necesidad del mismo
PT3360547T (pt) Composição farmacêutica bactericida que compreende ibuprofeno
DK3280447T3 (da) Farmaceutiske formuleringer
ZA201705620B (en) Millicapsule formulations comprising polyunsaturated free fatty acids
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
BR112017007754A2 (pt) composições de ácido graxo monoinsaturado e uso para o tratamento de aterosclerose.
BR112017012811A2 (pt) novo tratamento para doenças hepáticas gordurosas não alcoólicas
DK3107568T3 (da) Formuleringer til indgivelse til tyndtarmen
PL2952209T3 (pl) Jednorodne formulacje zawierające wielonienasycone kwasy tłuszczowe omega-3 (n-3 PUFA) i resweratrol do podawania doustnego
EP3134067C0 (en) VETERINARY COMPOSITION
PL3377044T3 (pl) Kompozycje ibuprofenu do bezpośredniego podawania doustnego
ES1180294Y (es) Camilla para intervenciones en bebes
IL250394B (en) Oral composition for delivery of drugs and other substances